Omega-3 and inflammation in hemodialysis
Phase 3
- Conditions
- End Stage Renal Disease.Chronic kidney disease, stage 5
- Registration Number
- IRCT201602012417N18
- Lead Sponsor
- Vice Chancellor for Research, Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
at least 18 years old; hemodialysis for at least 3 months; consent for cooperation; without usage of omega-3 during past 3 months
Exclusion criteria:
history of steatorrhea; malignancy; abnormal coagulation profile; need for anticoagulation therapy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Q-CRP level. Timepoint: At begining and after 6 months. Method of measurement: ELISA kit, mg/dL.;Serum TNF-a level. Timepoint: At begining and after 6 months. Method of measurement: ELISA kit, mg/dL.
- Secondary Outcome Measures
Name Time Method